eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâ€™s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-03-11	0.000200 $	0.00%	244
26-03-10	0.000200 $	0.00%	1,576
26-03-09	0.000200 $	0.00%	573
26-03-04	0.000200 $	-66.67%	403

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 11:05:48 2026-03-11 am EDT			5-day change	1st Jan Change
0.000200 ^USD	0.00%		0.00%	-

24-09-10	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
24-07-07	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI

Capitalization	940 812.25 733.31 701.32 1.28K 86.69K 1.31K 8.67K 3.46K 41.45K 3.53K 3.45K 149K	P/E ratio 2022	-0.78x	P/E ratio 2023	-0.71x
Enterprise value	2.18M 1.88M 1.7M 1.62M 2.96M 201M 3.04M 20.07M 8M 95.95M 8.16M 7.99M 346M	EV / Sales 2022	3,344,920x	EV / Sales 2023	-
Free-Float	96.84%	Yield 2022 *	-	Yield 2023	-

24-09-10	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
24-07-07	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI
24-07-01	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	CI
24-06-24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
24-06-24	Top Midday Decliners	MT
24-06-24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	MT
24-06-24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	CI
24-06-24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	CI
24-06-24	Effector Therapeutics, Inc. Announces Director Resignations	CI
24-06-24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
24-06-24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
24-05-20	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
24-05-09	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

23-08-24	HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	MT
23-05-26	Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	MT
23-05-10	Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	MT
23-03-09	Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	MT
23-01-09	JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	MT

eFFECTOR Therapeutics, Inc. Stock

Equities

EFTR

US28202V2079

Biotechnology & Medical Research

Valuation: eFFECTOR Therapeutics, Inc.

Chart: eFFECTOR Therapeutics, Inc.

Latest news: eFFECTOR Therapeutics, Inc.

Analysts' recommendations: eFFECTOR Therapeutics, Inc.

Press Releases: eFFECTOR Therapeutics, Inc.

Course Extremes

Managers and Directors: eFFECTOR Therapeutics, Inc.

ETFs: eFFECTOR Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

24-08-13	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
24-06-26	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24-06-24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
24-04-04	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
24-02-05	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.02
3 years	0		37
5 years	0		1,010.5
10 years	0		1,010.5

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EFFECTOR THERAPEUTICS, INC.	0.00%	0.00%	-66.67%	-100.00%	940
ARGENX SE	-1.03%	-1.53%	+20.96%	+95.67%	45.56B
WUXI APPTEC CO., LTD.	-1.34%	+0.95%	+50.72%	+15.79%	40.81B
INSMED INCORPORATED	-3.09%	-6.99%	+89.15%	+675.31%	31.01B
BIONTECH SE	+8.28%	-12.49%	-7.67%	-28.72%	21.05B
WUXI BIOLOGICS (CAYMAN) INC.	-3.27%	-1.47%	+47.97%	-30.44%	19.37B
GENMAB A/S	-1.84%	-2.06%	+27.10%	-28.71%	17.15B
AKESO, INC.	-2.35%	+10.10%	+56.84%	+183.23%	13.54B
SUMMIT THERAPEUTICS INC.	-1.53%	+4.55%	-13.08%	+979.19%	12.66B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.56%	+6.65%	+68.26%	-	12.33B
Average	-0.90%	+1.75%	+27.36%	+195.70%	21.35B
Weighted average by Cap.	-0.95%	-0.19%	+39.66%	+194.57%

	2022	2023
Net sales	3.55 3.07 2.77 2.65 4.83 327.65 4.97 32.76 13.06 156.67 13.33 13.05 564.3	-
Net income	-22.66M -19.58M -17.68M -16.91M -30.82M -2.09B -31.69M -209M -83.31M -999M -85.04M -83.25M -3.6B	-35.81M -30.94M -27.94M -26.72M -48.7M -3.3B -50.07M -330M -132M -1.58B -134M -132M -5.69B
Net Debt	-6.03M -5.21M -4.7M -4.5M -8.2M -556M -8.43M -55.6M -22.16M -266M -22.62M -22.15M -958M	2.18M 1.88M 1.7M 1.62M 2.96M 201M 3.04M 20.06M 8M 95.9M 8.16M 7.99M 345M